SecBot SecBot
PRESS-RELEASE ·Filed Apr 7, 2026

ANIP

ANI Pharmaceuticals, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

This publication strengthens ILUVIEN’s clinical profile but does not represent regulatory or commercial progress. Traders should monitor for future sales trends in ophthalmology, but no immediate revenue inflection is implied. The recent insider selling trend warrants caution on sentiment.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$79.47
T+0 close · Apr 7, 2026 · via day close
Latest settled
+8.25%
T+60 · $86.03
Vs SPY
−5.02%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 7 $79.47entry
  2. T+1 · 8mo ago −0.58%α −3.12% · $79.01
  3. T+5 · 7mo ago −1.48%α −6.81% · $78.29
  4. T+20 · 7mo ago +3.59%α −6.19% · $82.32
  5. T+60 · 5mo ago +8.25%α −5.02% · $86.03
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ANI Pharmaceuticals announced the publication of NEW DAY clinical trial results for ILUVIEN in the journal Ophthalmology, reinforcing clinical data for its use in diabetic macular edema (DME). This is a scientific validation rather than a new clinical or commercial development.

Key Facts

  • Results from the NEW DAY Phase 4 trial of ILUVIEN for diabetic macular edema were published in Ophthalmology, a peer-reviewed journal.
  • The trial results were previously disclosed in July 2025; this press release highlights peer-reviewed publication.
  • ILUVIEN is indicated for DME patients previously treated with corticosteroids without significant intraocular pressure rise.
  • Safety data show high incidence of cataract (82%), intraocular pressure elevation (34% had ≥10 mm Hg increase), and need for IOP-lowering treatment (38%).

Financial Impact

Minimal near-term financial impact; publication supports long-term clinical credibility but does not expand indications or drive immediate sales growth.

revenuemarket adoption

Risk Factors

  • High rate of cataract formation and IOP elevation may limit adoption despite efficacy.
  • Ongoing competition from anti-VEGF therapies for DME could constrain market penetration.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3268938

Track record

34 reports on ANIP

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +8.88% at T+60 after the Apr 8, 2026 report. 8 of 12 went positive at some point.

Filters
  1. Nov 18, 20263d ago Insider Cluster Neutral 2/10 Entry $69.13 Now $68.55 −0.84% settles Dec 18
  2. Nov 16, 20265d ago 144 Neutral 2/10 Entry $69.99 Now $68.55 −2.06% settles Dec 16
  3. Nov 16, 20266d ago 8-K Neutral 3/10 Entry $70.89 Now $68.55 −3.30% settles Dec 15
  4. Nov 9, 202612d ago Institutional Cluster Mixed 3/10 Entry $67.79 Now $68.55 +1.12% settles Dec 8
  5. Nov 5, 202616d ago 8-K Neutral 5/10 Entry $67.41 Now $68.55 +1.69% settles Dec 7
  6. Nov 5, 202617d ago 8-K Bullish 6/10 No price data
  7. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  8. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  9. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  10. Oct 29, 202623d ago 144 Neutral 2/10 Entry $72.00 Now $68.55 −4.79% settles Nov 30
Showing 10 of 34

US Market Status

Market Closed · Opens Mon (25h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 7, 2026